JW Pharmaceutical to Develop 'Patch-Type Hair Loss Treatment'... Signs MOU with Therajec Asia

Joint Research on Microneedle Hair Loss Treatment

JW Pharmaceutical announced on the 25th that it has signed a joint research agreement for micro-needle hair loss treatment with micro-needle research company Terazec Asia.

JW Pharmaceutical has signed a joint research agreement on microneedle hair loss treatment with microneedle research company Terazec Asia. Jin Se-ho, Head of Formulation Research Center at JW Pharmaceutical (left), and Kim Kyung-dong, CEO of Terazec Asia, are taking a commemorative photo after signing the agreement.
[Photo by JW Pharmaceutical]

Through this agreement, JW Pharmaceutical's Formulation Research Center will utilize Terazec Asia's platform to develop micro-needle hair loss treatments.

Micro-needles, also known as "patch injections," are transdermal drug delivery technology that uses ultra-fine needles about one-third the size of a hair to deliver drugs through the skin. When micro-needles are applied to the skin, the tiny needles penetrate and dissolve in the skin, injecting the drug into the body.

Micro-needles are gaining attention as next-generation drug delivery technology that can replace conventional injections or oral drugs, as they offer not only ease of administration but also faster recovery compared to injections and can be mass-produced at low cost. According to market research firm Future Market Insights, the global micro-needle pharmaceutical market, which was valued at $621.6 million (approximately 837 billion KRW) in 2019, is expected to grow to $1.2039 billion (approximately 1.62 trillion KRW) by 2030.

Terazec Asia secured an exclusive license for the original patent of pharmaceutical soluble micro-needles from Terazec in the United States in 2019 and has been focusing on standardization technology research and development for the commercialization of medical patches since 2020.

JW Pharmaceutical plans to develop treatments that enhance the efficacy of systemic circulation and topical drugs and improve the convenience of injection formulations through joint research with Terazec Asia.

Jin Se-ho, head of JW Pharmaceutical's Formulation Research Center, said, "We will focus on developing the optimal formulation that can replace injections based on Terazec Asia's micro-needle patch technology," adding, "By combining Terazec Asia's micro-needle technology with JW Pharmaceutical's new drug development capabilities, we will provide patients with convenient and effective treatments."

This content was produced with the assistance of AI translation services.